| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026 |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 04 Sep 2026 | S-8 |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 |
| 04 Aug 2026 |
Form 4: Gros David-Alexandre C, Director
Received 354,454 shares as a grant or award · Gave up 194,791 shares to cover exercise price or tax ($658K) |
| 04 Aug 2026 |
Form 4: Perrin Steven, Director
Received 152,353 shares as a grant or award · Gave up 72,138 shares to cover exercise price or tax ($244K) |
| 31 Jul 2026 | SCHEDULE 13G |
| 22 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Eledon Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as ... |
| 15 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | 10-Q |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study |
| 11 May 2026 | EFFECT |
| 07 May 2026 | CORRESP |
| 07 May 2026 | UPLOAD |
| 01 May 2026 | S-3 |
| 30 Apr 2026 | DEFA14A |
| 30 Apr 2026 | ARS |
| 30 Apr 2026 |
Proxy statement: annual meeting on June 18, 2026
CEO pay $3.2M, down 43% |
Loading...